Related references
Note: Only part of the references are listed.Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
C-H Hsu et al.
BRITISH JOURNAL OF CANCER (2010)
Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?
Fidel-David Huitzil-Melendez et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2010)
Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
Dieter Koeberle et al.
ONCOLOGIST (2010)
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
Andrew X. Zhu
BMC MEDICINE (2009)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Experimental mouse models for hepatocellular carcinoma research
Femke Heindryckx et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness
Adriana Sergio et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad et al.
AMERICAN JOURNAL OF SURGERY (2008)
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma - Results of a multicenter phase 2 study
Amani Asnacios et al.
CANCER (2008)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps
Augusto Villanueva et al.
CURRENT OPINION IN ONCOLOGY (2008)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis
Miroslaw Kornek et al.
LIVER INTERNATIONAL (2008)
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
Michael A. Zimmerman et al.
LIVER TRANSPLANTATION (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma
Taro Yamashita et al.
CANCER RESEARCH (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
Ignacio Duran et al.
CLINICAL CANCER RESEARCH (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
CANCER (2007)
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin
Robert G. Gish et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Targeting hypoxia cell signaling for cancer therapy
Giovanni Melillo
CANCER AND METASTASIS REVIEWS (2007)
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) -: Results of a phase II study
Samy Louafi et al.
CANCER (2007)
Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma
Lian-Yue Yang et al.
BMC CANCER (2006)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prospective validation of the Barcelona Clinic Liver Cancer staging system
U Cillo et al.
JOURNAL OF HEPATOLOGY (2006)
Genetics of hepatocellular tumors
P. Laurent-Puig et al.
ONCOGENE (2006)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
G D'Amico et al.
JOURNAL OF HEPATOLOGY (2006)
Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
SC Lee et al.
PHARMACOGENETICS AND GENOMICS (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
W Yeo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort
JA Marrero et al.
HEPATOLOGY (2005)
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
A Rapisarda et al.
CANCER RESEARCH (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
JS Lee et al.
HEPATOLOGY (2004)
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis
H Huynh et al.
BMC GASTROENTEROLOGY (2003)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials
C Cammà et al.
RADIOLOGY (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study
RTP Poon et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
